Through next-generation sequencing (NGS) analysis of circulating tumor DNA (ctDNA) and tumor tissue DNA (ttDNA) from these patients, mutations in PBRM1, SETD2, and ROS1 were frequently detected in both ctDNA and ttDNA of non-responders. This evidence concerns the gene PBRM1 and neoplasm.